Highly effective generic adjuvant systems for orphan or poverty-related vaccines - Wikidata - awgldk - TriplyDB

Highly effective generic adjuvant systems for orphan or poverty-related vaccines

Highly effective generic adjuvant systems for orphan or poverty-related vaccines

http://www.wikidata.org/entity/Q34307955

about

Structure, assembly, and DNA packaging of the bacteriophage T4 head Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccines Liposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs.Anthrax vaccine antigen-adjuvant formulations completely protect New Zealand white rabbits against challenge with Bacillus anthracis Ames strain spores.A CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys.Acetalated Dextran Microparticulate Vaccine Formulated via Coaxial Electrospray Preserves Toxin Neutralization and Enhances Murine Survival Following Inhalational Bacillus Anthracis Exposure.Adjuvants for human vaccines.Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines.Liposomal adjuvants for human vaccines.Bacteriophage T4 as a Nanoparticle Platform to Display and Deliver Pathogen Antigens: Construction of an Effective Anthrax Vaccine.Liposomes containing glucosyl ceramide specifically bind T4 bacteriophage: a self-assembling nanocarrier formulation.

P2860

Q26822645-5A2B09C8-4E20-4193-B2B9-F60B91E6DD2E Q28678943-F8A3D457-E858-437B-97AC-F99CC0F5EC80 Q33994987-847D268B-DF80-4561-8B28-B3C9EA40E0CE Q35666215-E8541EBC-B41D-4AA0-972B-B3A2D87CE8D6 Q35853440-5FBDE540-F1F0-49A6-892D-D82448D190EC Q36122915-310F7847-2F85-453C-9E41-6FCDA04BC78D Q38004229-8581FA60-A752-4E80-B494-016A8CAC0E5D Q38032881-F14D66C6-6D77-4E6D-864A-CA279B9ACBD2 Q38729260-901F1A24-D975-4262-A3DE-3D5A73220F0F Q40259573-C3C9E25F-EA98-48B1-82CE-D1E1183AE9D4 Q46781197-2FE73E47-890A-40E0-91F2-78991F113467

P2860

Highly effective generic adjuvant systems for orphan or poverty-related vaccines

http://www.wikidata.org/entity/Q34307955

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Highly effective generic adjuvant systems for orphan or poverty-related vaccines

@ast

Highly effective generic adjuvant systems for orphan or poverty-related vaccines

@en

Highly effective generic adjuvant systems for orphan or poverty-related vaccines

@nl

type

label

Highly effective generic adjuvant systems for orphan or poverty-related vaccines

@ast

Highly effective generic adjuvant systems for orphan or poverty-related vaccines

@en

Highly effective generic adjuvant systems for orphan or poverty-related vaccines

@nl

prefLabel

Highly effective generic adjuvant systems for orphan or poverty-related vaccines

@ast

Highly effective generic adjuvant systems for orphan or poverty-related vaccines

@en

Highly effective generic adjuvant systems for orphan or poverty-related vaccines

@nl

P1433

Q34307955-12DD4C62-9DB6-437F-8F7B-84A51DD5A1AE

P1476

Q34307955-EEC3E595-AA2A-4D66-AD97-C713C219A051

P2093

Q34307955-166C7C38-9A94-4886-82E9-27FD58018870

Q34307955-184BC8CD-9934-406D-9ACE-B4D9282E564F

Q34307955-6A847FD5-EDB5-471C-A965-9BBE2BE088BD

Q34307955-73816B21-0158-4AD3-872B-26D5199DE8FF

Q34307955-74C45F55-B46C-434F-A953-1AAF2800A906

Q34307955-875C7FBD-705B-4B1E-9877-C8B79FFDEF44

Q34307955-8E3103E5-3869-41D2-89EE-CF16674671B8

Q34307955-97F2E016-4EB7-4AC6-99B7-5D521EAA87E7

Q34307955-B089E6A1-D901-4394-803C-B5ACED24A88F

Q34307955-E38D5988-9500-4C65-936E-9A7F7B6D75DF

P2860

Q34307955-0F322CE1-8E77-4446-B17A-E33360B3D435

Q34307955-18E18193-2397-4446-B09A-6D687D33844D

Q34307955-1E24E8AC-BB4F-4F5B-BBE6-46ADD4908D83

Q34307955-44F8C706-3FC6-4B12-9288-6A8F65AEDA04

Q34307955-48B6B897-CD0D-4269-BE8A-18D620DEF446

Q34307955-4DC8E93F-D0D0-4801-82EC-802057A96532

Q34307955-596D946B-3033-4C3A-92CA-551F23ACEB3C

Q34307955-5A42D4E9-FEEE-474A-AE9B-90636AB9440B

Q34307955-5E872831-5923-4178-87F2-C8EDD41FBF1F

Q34307955-7A4DA9D1-4EB3-4B51-926B-4939CD07A690

P304

Q34307955-4BA893EB-20D2-42CE-97EC-20DA2B259D9F

P31

Q34307955-40C98966-37A0-48F6-83C6-A6E24F4C28E2

P356

Q34307955-BA759BAE-E2EF-4523-8CDD-88DF523002BB

P407

Q34307955-53A0FFBF-71FD-4C54-A2BF-79AE5731A389

P433

Q34307955-658B500B-153F-40DC-9DB4-7AA1259AECD8

P478

Q34307955-4FEE030C-699B-4CAA-BDBC-C040D5D9B44B

P577

Q34307955-0B1E3725-85FC-4377-8170-9D8C6DDF5D0D

P5875

Q34307955-A169AB50-EEB3-49DD-9DF3-A2CABFD16061

P698

Q34307955-4EDED5BB-4772-41E1-8BD0-FEDF4DD65BBD

P921

Q34307955-2D7ABE8D-8BF7-4AFB-BE08-02027C9EA546

P932

Q34307955-88AE0FE8-2C17-4495-A680-B9BF9CE5D216

P356

J.VACCINE.2010.11.049

P1433

P1476

Highly effective generic adjuvant systems for orphan or poverty-related vaccines

@en

P2093

Carl R Alving

http://www.w3.org/2001/XMLSchema#string

Carmen Fernandez-Prada

http://www.w3.org/2001/XMLSchema#string

Gary R Matyas

http://www.w3.org/2001/XMLSchema#string

Kristina K Peachman

http://www.w3.org/2001/XMLSchema#string

Mangala Rao

http://www.w3.org/2001/XMLSchema#string

Qin Li

http://www.w3.org/2001/XMLSchema#string

Richard Borschel

http://www.w3.org/2001/XMLSchema#string

Sathish B Shivachandra

http://www.w3.org/2001/XMLSchema#string

Venee I Morthole

http://www.w3.org/2001/XMLSchema#string

Venigalla B Rao

http://www.w3.org/2001/XMLSchema#string

P2860

Structure of the Small Outer Capsid Protein, Soc: A Clamp for Stabilizing Capsids of T4-like Phages

Aluminum salts in vaccines--US perspective

Anthrax vaccination strategies

Production, recovery and immunogenicity of the protective antigen from a recombinant strain of Bacillus anthracis.

In vitro binding of anthrax protective antigen on bacteriophage T4 capsid surface through Hoc-capsid interactions: a strategy for efficient display of large full-length proteins.

Correlation between lethal toxin-neutralizing antibody titers and protection from intranasal challenge with Bacillus anthracis Ames strain spores in mice after transcutaneous immunization with recombinant anthrax protective antigen.

Anthrax LFn-PA Hybrid Antigens: Biochemistry, Immunogenicity, and Protection Against Lethal Ames Spore Challenge in Rabbits.

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives.

Design and selection of vaccine adjuvants: animal models and human trials.

Survey of human-use adjuvants.

P304

873-877

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2010.11.049

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49642785

http://www.w3.org/2001/XMLSchema#string

P698

21115053

http://www.w3.org/2001/XMLSchema#string

P921

P932

4190060

http://www.w3.org/2001/XMLSchema#string